Barely a month after joining Merck & Co. through a $10-billion merger, Verona Pharma has withdrawn its EU marketing application for Ohtuvayre (ensifentrine), the inhaled PDE3/4 inhibitor touted as a key addition to Merck's cardio-pulmonary portfolio. The filing was pulled on Oct. 30 as the European Medicines Agency (EMA) was still evaluating initial information from the company, leaving the review process unfinished and without any recommendations from the regulator. Ohtuvayre was approved in th

The FDA on Friday approved a more restrictive label for Sarepta Therapeutics' Elevidys (delandistrogene moxeparvovec-rokl) gene therapy, adding a boxed warning for acute serious liver injury and acute liver failure, including fatal outcomes, while confining its use to ambulatory Duchenne muscular dystrophy (DMD) patients at least four years old.The update follows two fatal cases of acute liver failure in non-ambulatory boys earlier this year. The FDA said another serious, non-fatal case of acute

Fresh off the high-profile bidding war that saw Pfizer beat out Novo Nordisk for obesity-drug developer Metsera, another takeover tussle may be on the horizon – this time in the market for medicines to treat sleep disorders.Avadel Pharmaceuticals said Friday that it has received an unsolicited bid from Lundbeck, a surprise move that is now casting doubt over Avadel's existing agreement to be acquired by Alkermes. Shares in Avadel jumped over 20% on the news, giving it a market cap of about $2.3

TandemAI announced Thursday that it closed a $22 million series A extension to advance further development of TandemViz, its drug discovery platform. The round, led by KHK Fund and V-Capital, brings the company's total funding to over $80 million. TandemAI's end-to-end platform combines physics-based computational tools and AI in silico design software with wet lab capabilities in a single interface. The company's suite of in silico drug discovery and design tools includes molecular dynamics and

Venture capital firm Medicxi closed its fifth fund at €500 million ($581.4 million) on Friday, bringing its total capital raised in the past 10 years to over €2 billion. From the oversubscribed fund, Medicxi will invest in biotechs developing innovative products, per its asset-centric investment model, including existing companies at any stage of development if they align with the firm's value creation strategy. Since its $400-million fourth fund closed in 2023, the VC has created 16 newcos, and

Merck & Co. agreed to buy Cidara Therapeutics for $221.50 per share in cash, or approximately $9.2 billion, adding a late-stage antiviral designed to prevent influenza infection to its pipeline. "We intend to build on the Cidara team's remarkable progress and are confident that CD388 has the potential to be another important driver of growth through the next decade," remarked Merck CEO Robert Davis.Cidara's CD388 is designed to provide universal protection against seasonal and pandemic flu strai

Bristol Myers Squibb and Johnson & Johnson have two shots left at posting a late-stage success for milvexian after one pivotal trial of the experimental oral Factor XIa (FXIa) inhibitor came up short. The news sent shares in BMS down as much as 5% in premarket trading on Friday.According to the companies, the decision to halt the Librexia ACS study — investigating milvexian when added to conventional antiplatelet therapy for patients after a recent acute coronary syndrome (ACS) event — was taken

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to the Com

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 700,000 common shares on the same terms and conditions. Fennec anticipa

New Delhi: Contract Development and Manufacturing Organisation (CDMO) Akums Drugs & Pharmaceuticals reported a 35.9 per cent year-over-year (YoY) decline in net profit, to Rs 43 crore in the quarter ended September this year. Revenue from operations fell 1.5 per cent YoY to Rs 1,018 crore against Rs 1,033 crore recorded in the year ago period. Ebitda for the period stood at Rs 94 crore, at a margin of 9.3 per cent. For the July-September quarter, Akums' CDMO business revenue saw a marginal incre